University of Hong Kong, China

Email: scwtang@hku.hk

Qualifications

2005 Ph.D., the University of Hong Kong

1991 M.B., B.S., the University of Hong Kong

Publications (Selected)

1. Heerspink, H. J., Agarwal, R., Bakris, G. L., Cherney, D. Z., Lam, C. S., Neuen, B. L., ... & Maeda, Y. (2025). Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrology Dialysis Transplantation, 40(2), 308-319.
2. Ma, J., Yiu, W. H., & Tang, S. C. (2025). Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease. Diabetic Medicine, 42(2), e15427.
3. Teerawattananon, Y., Chavarina, K. K., Phannajit, J., Sutawong, J., Yongphiphatwong, N., Tang, S. C., ... & Jha, V. (2025). The Access to Dialysis in Low-and Middle-Income Countries Commission: lessons for universal health coverage. Nature Medicine, 31(1), 19-21.
4. Ye, S., Zhang, M., Tang, S. C., Li, B., & Chen, W. (2024). PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms. Molecular Biology Reports, 51(1), 304.
5. Ayoub, I., Tang, S., Kooienga, L., Preciado, P., Lee, D. S., Moody, S., & Rovin, B. H. (2024). Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors in Adults with IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial: FR-PO849. Journal of the American Society of Nephrology, 35(10S), 10-1681.
6. Makmun, A., Satirapoj, B., Foo, M. W., Danguilan, R., Gulati, S., Kim, S., ... & Tang, S. C. (2024). The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions. Korean Journal of Nephrology.
7. Chan, J. Y., Cheng, Y. L., Yuen, S. K., Wong, P. N., Cheng, H. M., Mo, K. L., ... & Lui, S. L. (2024). The Hong Kong Renal Registry: a recent update. Hong Kong Med J, 30(4), 332-336.
8. Chan, K. W., Kwong, A. S. K., Tsui, P. N., Chan, G. C. W., Choi, W. F., Yiu, W. H., ... & READY and SCHEMATIC research group. (2024). Add-on astragalus in type 2 diabetes and chronic kidney disease: a multi-center, assessor-blind, randomized controlled trial. Phytomedicine, 130, 155457.
9. Heerspink, H. J., Cherney, D., Gafor, A. H. A., Górriz, J. L., Pergola, P. E., Tang, S. C., ... & Nangaku, M. (2024). Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials. Journal of the American Society of Nephrology, 10-1681.
10. Xue, R., Yiu, W. H., Chan, K. W., Lok, S. W., Zou, Y., Ma, J., ... & Tang, S. C. (2024). Long non-coding RNA Neat1, NLRP3 inflammasome, and acute kidney injury. Journal of the American Society of Nephrology, 10-1681.
11. Fung, W. W. S., Park, H. C., Hirakawa, Y., Arruebo, S., Bello, A. K., Caskey, F. J., ... & Zhou, L. (2024). Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney International Supplements, 13(1), 97-109.
12. Fung, W. W. S., Park, H. C., Hirakawa, Y., Arruebo, S., Bello, A. K., Caskey, F. J., ... & Zhou, L. (2024). Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney International Supplements, 13(1), 97-109.
13. Rovin, B. H., Barratt, J., Heerspink, H. J., Alpers, C. E., Bieler, S., Chae, D. W., ... & Chrysochou, C. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet, 402(10417), 2077-2090.
14. Smeijer, J. D., Kohan, D. E., Rossing, P., Correa-Rotter, R., Liew, A., Tang, S. C., ... & Lambers Heerspink, H. J. (2023). Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. Cardiovascular Diabetology, 22(1), 251.
15. Nangaku, M., Kitching, A. R., Boor, P., Fornoni, A., Floege, J., Coates, P. T., ... & Zhang, A. (2023). International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. Kidney international, 104(1), 36-45.
16. Heerspink, H. J., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., ... & Uhlinova, J. (2023). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. The Lancet, 401(10388), 1584-1594.
17. Yiu, W. H., Lok, S. W., Xue, R., Chen, J., Lai, K. N., Lan, H. Y., & Tang, S. C. (2023). The long noncoding RNA Meg3 mediates TLR4-induced inflammation in experimental obstructive nephropathy. Clinical Science, 137(5), 317-331.

Profile Details

WoS ResearcherID: C-4411-2009

https://orcid.org/0000-0002-6862-1941

https://medic.hku.hk/en/Staff/University-Academic-Staff/Prof-TANG-Chi-Wai,-Sydney/Prof-TANG-Chi-Wai-Sydney-Profile

https://scholar.google.com/citations?user=EqJMjDgAAAAJ&hl=en

https://www.scopus.com/authid/detail.uri?authorId=7403437082